ReviewJournal of molecular and cellular cardiology2022
Reverse cardio-oncology: Exploring the effects of cardiovascular disease on cancer pathogenesis.
Review in Journal of molecular and cellular cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 69 citations in OpenAlex.
- The impact of effective dose to the immune cells on survival in breast cancer patients.Clinical and translational radiation oncology · 2026Article
- Cardiovascular disease incidence and cancer risk in two large European prospective cohorts.International journal of cancer · 2026Article
- Review
- The role of angiotensin II in cardiovascular disease-induced cancer growth.Cardio-oncology (London, England) · 2026Article
- Hypertension-cancer recurrence crosstalk: implications for survivorship care.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Look Who Is Talking: Extracellular Vesicles as Mediators of Intercellular and Interorgan Communication.Comprehensive Physiology · 2026Review
- Bidirectional Association between Atrial Fibrillation and Ovarian Cancer: Evidence from the UK Biobank and Mendelian Randomization.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- Interplay between acute Type A aortic dissection and pan-cancer: Clinical evidence, bioinformatics, and experimental validation.iScience · 2025Article
- Evolving tumor microenvironment: Driving cancer initiation and progression in cardiovascular diseases.iScience · 2025Review
- Associations of low-density lipoprotein cholesterol and hemoglobin A1C with cardiovascular events and mortality in breast and prostate cancer patients.International journal of cardiology. Cardiovascular risk and prevention · 2025Article
- CT-Based Pericardial Composition Change as an Imaging Biomarker for Radiation-Induced Cardiotoxicity.Cancers · 2025Article
- Update on preclinical models of cancer therapy-related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio-Oncology, and the ESC Working Group on Cellular Biology of the Heart.European journal of heart failure · 2025Review
- Cancer Outcomes Following Coronary Revascularization: Should We Be Looking Beyond Bleeding?Journal of the American Heart Association · 2025Article
- Long-term cardiac MRI follow up of MANTICORE (Multidisciplinary Approach to Novel Therapies in Cardio-Oncology REsearch).Cardio-oncology (London, England) · 2025Article
- Cancer Development and Progression in Patients with Heart Failure.Current heart failure reports · 2024Review
- Time Relationship between the Occurrence of a Thromboembolic Event and the Diagnosis of Hematological Malignancies.Cancers · 2024Article
- Hallmarks of cancer in patients with heart failure: data from BIOSTAT-CHF.Cardio-oncology (London, England) · 2024Article
- Complications and comorbidities associated with antineoplastic chemotherapy: Rethinking drug design and delivery for anticancer therapy.Acta pharmaceutica Sinica. B · 2024Review
- Article
- Small Extracellular Vesicles From Infarcted and Failing Heart Accelerate Tumor Growth.Circulation · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
Abstract
The field of cardio-oncology has emerged in response to the increased risk of cardiovascular disease (CVD) in patients with cancer. However, recent studies suggest a more complicated CVD-cancer relationship, wherein development of CVD, either prior to or following a cancer diagnosis, can also lead to increased risk of cancer and worse outcomes for patients. In this review, we describe the current evidence base, across epidemiological as well as preclinical studies, which supports the emerging concept of 'reverse-cardio oncology', or CVD-induced acceleration of cancer pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.